You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四環醫藥(00460.HK)旗下醫用疤痕修復類三款產品獲批
格隆匯 02-28 12:30

格隆匯2月28日丨四環醫藥(00460.HK)宣佈,集團旗下渼顏空間生物科技(吉林)有限公司所研發的醫用疤痕修復液、醫用疤痕修復膜及醫用矽酮疤痕凝膠獲得中國國家藥品監督管理局頒發的醫療器械註冊證。

醫用疤痕修復液和醫用疤痕修復膜可用於輔助改善皮膚病理性疤痕,輔助預防皮膚病理性疤痕的形成;醫用矽酮疤痕凝膠用於輔助預防和輔助改善因燒燙傷、創傷、體表外傷、手術原因引起的增生性疤痕。三款醫用疤痕修復類產品均為II類醫療器械。渼顏空間自研的三款醫用疤痕修復類產品主要聚焦於解決醫美術後的傷口癒合及疤痕修復這兩大痛點。不僅能通過適合、安全、無刺激的輔助修復讓術後效果更理想,也與集團的多款醫美產品具備很好的協同效用,在年內上市後能夠形成有效且互補的產品組合。

根據QYResearch報吿,瘢痕治療方式中主要用於局部外用治療的包括凝膠、乳膏和疤痕貼等。預計2020年中國局部外用疤痕治療市場規模為7524萬美元,並將在2026年達到1.1億美元。

此次醫用疤痕修復液、醫用疤痕修復膜和醫用矽酮疤痕凝膠三款產品獲批,是渼顏空間繼童顏水凝嘉樂妍®、醫用皮膚護理凝膠及醫用皮膚修復凝膠獲批後又新增的三款自研產品,不僅證明了渼顏空間強大的研發實力和快速註冊的能力,同時也標誌着集團醫美產品自研管線的進一步落地,而且豐富和擴大了集團醫美平台渼顏空間的產品組合。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account